150 related articles for article (PubMed ID: 33887113)
21. Total plasma volume determinations for patients with potentially challenging conditions requiring therapeutic plasma exchange: Dealer's choice.
Rosenbaum L; Johnson M; Li M; Raval JS
J Clin Apher; 2020 Apr; 35(2):138-139. PubMed ID: 31774189
[No Abstract] [Full Text] [Related]
22. Physiological role of plasma and its components and the clinical implications of different methods of apheresis: A narrative review.
Ahmadpoor P; Aglae C; Cariou S; Pambrun E; Renaud S; Garo F; Darmon R; Schultz C; Prelipcean C; Reboul P; Moranne O
Ther Apher Dial; 2021 Jun; 25(3):262-272. PubMed ID: 32710797
[TBL] [Abstract][Full Text] [Related]
23. Technical and clinical experience with protein A immunoadsorption columns.
Belàk M; Borberg H; Jimenez C; Oette K
Transfus Sci; 1994 Dec; 15(4):419-22. PubMed ID: 10155559
[TBL] [Abstract][Full Text] [Related]
24. Regional citrate anticoagulation--a safe and effective procedure in pediatric apheresis therapy.
Kreuzer M; Ahlenstiel T; Kanzelmeyer N; Ehrich JH; Pape L
Pediatr Nephrol; 2011 Jan; 26(1):127-32. PubMed ID: 20963447
[TBL] [Abstract][Full Text] [Related]
25. The lipid- and lipoprotein- [LDL-Lp(a)] apheresis techniques. Updating.
Stefanutti C; Morozzi C; Perrone G; Di Giacomo S; Vivenzio A; D'Alessandri G
G Chir; 2012; 33(11-12):444-9. PubMed ID: 23140934
[TBL] [Abstract][Full Text] [Related]
26. Guillain-Barré syndrome treated by membrane plasma exchange and/or immunoadsorption.
Marn Pernat A; Buturović-Ponikvar J; Svigelj V; Ponikvar R
Ther Apher Dial; 2009 Aug; 13(4):310-3. PubMed ID: 19695065
[TBL] [Abstract][Full Text] [Related]
27. The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1.
Empen K; Otto C; Brödl UC; Parhofer KG
J Clin Apher; 2002; 17(1):38-43. PubMed ID: 11948705
[TBL] [Abstract][Full Text] [Related]
28. Indications, technique, and outcome of therapeutic apheresis in European pediatric nephrology units.
Paglialonga F; Schmitt CP; Shroff R; Vondrak K; Aufricht C; Watson AR; Ariceta G; Fischbach M; Klaus G; Holtta T; Bakkaloglu SA; Zurowska A; Jankauskiene A; Vande Walle J; Schaefer B; Wright E; Connell R; Edefonti A
Pediatr Nephrol; 2015 Jan; 30(1):103-11. PubMed ID: 25135618
[TBL] [Abstract][Full Text] [Related]
29. [Is apheresis still a useful tool in the treatment of nephrological diseases?].
Santoro A
G Ital Nefrol; 2019 Apr; 36(2):. PubMed ID: 30983168
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic plasma exchange: Experience in a third level hospital, 2013-2016, Lima (Peru).
Palma-Garcia L; Velásquez-Rimachi V; Pezo-Pezo A; Roig J; Perez-Villegas J
J Clin Apher; 2018 Aug; 33(4):480-485. PubMed ID: 29536568
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic plasma exchange using the Spectra Optia cell separator compared with the COBE Spectra.
Kim DK; Kim S; Jeong SH; Kim HO; Kim HJ
Ann Lab Med; 2015 Sep; 35(5):506-9. PubMed ID: 26206687
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic apheresis of immune diseases in nephrology department.
Visvardis G; Manou E; Griveas I; Meimaridou D; Mitsopoulos E; Kyriklidou P; Papadopoulou D; Ginikopoulou E; Rottstein L; Sakellariou G
Ren Fail; 2004 Sep; 26(5):569-74. PubMed ID: 15526917
[TBL] [Abstract][Full Text] [Related]
33. Establishing an institutional therapeutic apheresis registry.
Mann SA; McCleskey B; Marques MB; Adamski J
J Clin Apher; 2016 Dec; 31(6):516-522. PubMed ID: 26801326
[TBL] [Abstract][Full Text] [Related]
34. The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection.
Ahmed T; Senzel L
J Clin Apher; 2012; 27(4):173-7. PubMed ID: 22411078
[TBL] [Abstract][Full Text] [Related]
35. [Prevention of early graft occlusion after coronary bypass grafting by post-operative reduction of plasma fibrinogen by H.E.L.P. apheresis. First evaluation of 12 patients treated during our study (44 bypasses)].
Blessing F; Jaeger BR; Oberhoffer M; Reichart B; Seidel D
Z Kardiol; 2003; 92(Suppl 3):III42-7. PubMed ID: 14663601
[TBL] [Abstract][Full Text] [Related]
36. Fibrinogen is not a prognostic factor for response to HELP-apheresis in sudden sensorineural hearing loss (SSHL).
Berger T; Kaiser T; Scholz M; Bachmann A; Ceglarek U; Hesse G; Hagemeyer B; Stumvoll M; Thiery J; Dietz A
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3693-703. PubMed ID: 25527412
[TBL] [Abstract][Full Text] [Related]
37. The use of therapeutic apheresis in cardiovascular disease.
Pignalosa O; Infante T; Napoli C
Transfus Med; 2014 Apr; 24(2):68-78. PubMed ID: 24720382
[TBL] [Abstract][Full Text] [Related]
38. The ABC of apheresis.
Dierickx D; Macken E
Acta Clin Belg; 2015 Apr; 70(2):95-9. PubMed ID: 25366579
[TBL] [Abstract][Full Text] [Related]
39. [Apheresis of immunoglobulins - new approach to the treatment of severe dilated cardiomyopathy].
Konovalov GA; Belenkov IuN; Zvezdkin PV; Chebyshev AN; Semin SN; Kuznetsova IuV; Adamova IIu; Kipor SG; Pokrovskiĭ SN
Kardiologiia; 2002; 42(6):92-6. PubMed ID: 12494138
[TBL] [Abstract][Full Text] [Related]
40. Pediatric Therapeutic Apheresis: A Critical Appraisal of Evidence.
Meyer EK; Wong EC
Transfus Med Rev; 2016 Oct; 30(4):217-22. PubMed ID: 27555064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
